HC Wainwright Has Positive Forecast for BCRX Q2 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Research analysts at HC Wainwright lifted their Q2 2025 earnings estimates for shares of BioCryst Pharmaceuticals in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $0.10 for the quarter, up from their prior forecast of ($0.01). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.56 EPS, FY2027 earnings at $0.88 EPS and FY2028 earnings at $1.29 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. During the same period in the previous year, the company earned $0.28 earnings per share. The business’s quarterly revenue was up 40.8% on a year-over-year basis.

BCRX has been the subject of several other reports. JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Cantor Fitzgerald began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 price target for the company. Evercore ISI increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. JPMorgan Chase & Co. boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Wedbush began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $16.56.

BioCryst Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ BCRX opened at $9.98 on Thursday. BioCryst Pharmaceuticals has a twelve month low of $5.23 and a twelve month high of $11.11. The firm has a market cap of $2.09 billion, a PE ratio of -16.36 and a beta of 1.08. The business has a fifty day simple moving average of $7.87 and a two-hundred day simple moving average of $7.89.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $32,000. GF Fund Management CO. LTD. purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $33,000. GAMMA Investing LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $46,000. Finally, R Squared Ltd purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $48,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.